NCT00002988View on ClinicalTrials.gov

Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

April 30, 1997

Primary Completion Date

November 30, 2000

Study Completion Date

November 30, 2000

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

carmustine

DRUG

irinotecan hydrochloride

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER